# Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer

> **NCT05348668** · PHASE2 · COMPLETED · sponsor: **Anhui Provincial Hospital** · enrollment: 78 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors

## Key facts

- **NCT ID:** NCT05348668
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05348668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05348668, "Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05348668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*